Takeda Wins Japan Approval for ORZEYFUL in Narcolepsy
OSAKA, Japan & CAMBRIDGE, Massachusetts, Aug 24, 2026 Takeda Pharmaceutical Company Limited announced that Japan’s Ministry of Health, Labour...
Takeda
Advertisement
Takeda Reports Strong Phase 3 Zasocitinib Results
Osaka, Japan & Cambridge, Mass., July 16, 2026 Takeda announced new Phase 3 data demonstrating that its investigational oral...
Insilico Secures Up to $600M Takeda AI Discovery Deal
CAMBRIDGE, Mass., July 2, 2026 Insilico Medicine has entered into a strategic collaboration with Takeda to accelerate the discovery...
Takeda Deploys Boltz AI Models to Accelerate Drug Discovery
CAMBRIDGE, Mass., June 20, 2026 Takeda and Boltz PBC have entered into a strategic collaboration aimed at accelerating the...
Takeda Oveporexton Shows Broad Benefits in Narcolepsy
OSAKA, Japan and CAMBRIDGE, Massachusetts, June 15, 2026 Takeda has unveiled new pivotal Phase 3 data demonstrating that oveporexton...
Advertisements
Takeda’s Zasocitinib Outperforms Deucravacitinib in Psoriasis
STOCKHOLM, Sweden, June 11OSAKA, Japan and CAMBRIDGE, Massachusetts, June 11, 2026, 2026 Takeda has announced positive topline results from...
Takeda’s ENTYVIO Nears Pediatric IBD FDA Approval
OSAKA, Japan and CAMBRIDGE, Massachusetts, June 9, 2026 Takeda has reached a significant regulatory milestone with the U.S. Food...
Innovent’s IBI363 Shows Strong First-Line NSCLC Data
SAN FRANCISCO and SUZHOU, China, May 22, 2026 Innovent Biologics announced encouraging preliminary Proof-of-Concept (PoC) clinical data for IBI363,...
Innovent Secures Third NMPA Breakthrough Status for IBI363
SAN FRANCISCO and SUZHOU, China, May 10, 2026 Innovent Biologics, Inc. announced that China’s National Medical Products Administration (NMPA)...
AC Immune Advances ACI-24 Alzheimer’s Trial Expansion
LAUSANNE, Switzerland, April 2026 AC Immune SA announced continued progress in its Phase 1b/2 ABATE clinical trial evaluating ACI-24,...
Advertisement
